Frederick G. Hayden
Global Influenza Programme
World Health Organization
Geneva
Switzerland
Name/email consistency: high
- Developing new antiviral agents for influenza treatment: what does the future hold? Hayden, F. Clin. Infect. Dis. (2009)
- Antivirals for influenza: historical perspectives and lessons learned. Hayden, F.G. Antiviral Res. (2006)
- Respiratory viral threats. Hayden, F.G. Curr. Opin. Infect. Dis. (2006)
- Antiviral management of seasonal and pandemic influenza. Hayden, F.G., Pavia, A.T. J. Infect. Dis. (2006)
- Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. Hayden, F., Klimov, A., Tashiro, M., Hay, A., Monto, A., McKimm-Breschkin, J., Macken, C., Hampson, A., Webster, R.G., Amyard, M., Zambon, M. Antivir. Ther. (Lond.) (2005)
- Rhinovirus and the lower respiratory tract. Hayden, F.G. Rev. Med. Virol. (2004)
- Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. Hayden, F.G., Belshe, R., Villanueva, C., Lanno, R., Hughes, C., Small, I., Dutkowski, R., Ward, P., Carr, J. J. Infect. Dis. (2004)
- Pandemic influenza: is an antiviral response realistic?. Hayden, F.G. Pediatr. Infect. Dis. J. (2004)
- Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Hayden, F.G., Herrington, D.T., Coats, T.L., Kim, K., Cooper, E.C., Villano, S.A., Liu, S., Hudson, S., Pevear, D.C., Collett, M., McKinlay, M. Clin. Infect. Dis. (2003)
- Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Hayden, F.G., Turner, R.B., Gwaltney, J.M., Chi-Burris, K., Gersten, M., Hsyu, P., Patick, A.K., Smith, G.J., Zalman, L.S. Antimicrob. Agents Chemother. (2003)
- Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in phase II clinical trials. Hayden, F.G., Coats, T., Kim, K., Hassman, H.A., Blatter, M.M., Zhang, B., Liu, S. Antivir. Ther. (Lond.) (2002)
- Perspectives on antiviral use during pandemic influenza. Hayden, F.G. Philos. Trans. R. Soc. Lond., B, Biol. Sci. (2001)
- Oral oseltamivir in human experimental influenza B infection. Hayden, F.G., Jennings, L., Robson, R., Schiff, G., Jackson, H., Rana, B., McClelland, G., Ipe, D., Roberts, N., Ward, P. Antivir. Ther. (Lond.) (2000)
- Influenza virus and rhinovirus-related otitis media: potential for antiviral intervention. Hayden, F.G. Vaccine (2000)
- Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. Hayden, F.G., Treanor, J.J., Fritz, R.S., Lobo, M., Betts, R.F., Miller, M., Kinnersley, N., Mills, R.G., Ward, P., Straus, S.E. JAMA (1999)